Literature DB >> 7012835

Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein.

D J Knauer, G L Smith.   

Abstract

Multiplication-stimulating activity (MSA) produced by Buffalo rat liver cells (BRL-3A) in culture is related to the somatomedin family of growth regulatory polypeptides. MSA will stimulate glucose transport and DNA synthesis in normal chicken embryo fibroblasts (CEF) at concentrations of 10-200 ng/ml. MSA found in BRL-3A-conditioned medium, like the somatomedins in serum, does not exist as the free hormone but is bound to a specific high molecular weight carrier protein. In this report we demonstrate that purified MSA carrier protein (MCP) inhibits the biological activity of MSA on CEF as measured by the stimulation of glucose transport and DNA synthesis. In addition, purified MCP competitively inhibits the binding of 125I-labeled MSA to these cells. In control experiments in which insulin was used as the mitogenic agent, MCP had no effect on these biological responses. These results indicate that the inhibitory effect of MCP is the result of specific interaction with MSA and support the hypothesis that cells may be unresponsive to somatomedins bound to their serum carrier proteins.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7012835      PMCID: PMC350480          DOI: 10.1073/pnas.77.12.7252

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  The purification and partial characterization of an insulin-like protein from human serum.

Authors:  P L Poffenbarger
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

2.  Interaction of multiplication-stimulating activity with chick embryo fibroblasts demonstrates a growth receptor.

Authors:  M M Rechler; J M Podskalny; S P Nissley
Journal:  Nature       Date:  1976-01-15       Impact factor: 49.962

3.  Binding of nonsuppressible insulinlike activity to human serum. Evidence for a carrier protein.

Authors:  J Zapf; M Waldvogel; E R Froesch
Journal:  Arch Biochem Biophys       Date:  1975-06       Impact factor: 4.013

4.  Specific binding of a somatomedin-like polypeptide in rat serum depends on growth hormone.

Authors:  A C Moses; S P Nessley; K L Cohen; M M Rechler
Journal:  Nature       Date:  1976-09-09       Impact factor: 49.962

5.  Somatomedin: proposed designation for sulphation factor.

Authors:  W H Daughaday; K Hall; M S Raben; W D Salmon; J L van den Brande; J J van Wyk
Journal:  Nature       Date:  1972-01-14       Impact factor: 49.962

6.  Topics in the methodology of substitution reactions with agarose.

Authors:  I Parikh; S March; P Cuatercasas
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

7.  Purified multiplication-stimulating activity from rat liver cell conditioned medium: comparison of biological activities with calf serum, insulin, and somatomedin.

Authors:  G L Smith; H M Temin
Journal:  J Cell Physiol       Date:  1974-10       Impact factor: 6.384

8.  A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts.

Authors:  N C Dulak; H M Temin
Journal:  J Cell Physiol       Date:  1973-04       Impact factor: 6.384

9.  Multiplication-stimulating activity for chicken embryo fibroblasts from rat liver cell conditioned medium: a family of small polypeptides.

Authors:  N C Dulak; H M Temin
Journal:  J Cell Physiol       Date:  1973-04       Impact factor: 6.384

10.  The serum half-life of somatomedin activity: evidence for growth hormone dependence.

Authors:  K L Cohen; S P Nissley
Journal:  Acta Endocrinol (Copenh)       Date:  1976-10
View more
  22 in total

Review 1.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

3.  Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.

Authors:  M Ross; G L Francis; L Szabo; J C Wallace; F J Ballard
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

4.  Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays.

Authors:  Katrin Tiemann; Carolina Garri; Jeffrey Wang; Lauren Clarke; Kian Kani
Journal:  J Vis Exp       Date:  2018-09-19       Impact factor: 1.355

5.  The gene encoding human low-molecular weight insulin-like growth-factor binding protein (IGF-BP25): regional localization to 7p12-p13 and description of a DNA polymorphism.

Authors:  T Alitalo; K Kontula; R Koistinen; K Aalto-Setälä; M Julkunen; O A Jänne; M Seppälä; A de la Chapelle
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

6.  An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.

Authors:  R G Elgin; W H Busby; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

7.  Sustained release of epidermal growth factor accelerates wound repair.

Authors:  A Buckley; J M Davidson; C D Kamerath; T B Wolt; S C Woodward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

8.  Production of insulin-like growth factor binding proteins (IGFBPs) by human endometrial stromal cell is stimulated by the presence of embryos.

Authors:  H C Liu; C Mele; D Catz; N Noyes; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1995-02       Impact factor: 3.412

9.  Expression and regulation of insulin-like growth factor binding protein-1 in the rat uterus throughout estrous cycle.

Authors:  A Ghahary; J Luo; L J Murphy
Journal:  Mol Cell Biochem       Date:  1993-07-07       Impact factor: 3.396

10.  Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.

Authors:  R Meyer-Schwickerath; A Pfeiffer; W F Blum; H Freyberger; M Klein; C Lösche; R Röllmann; H Schatz
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.